Dr. James Chim to Receive Asian Myeloma Network Distinguished Service Award at the 9th AMN Summit in Nagoya
International Myeloma Foundation (IMF) to hold AMN Awards Ceremony at the 9th AMN Summit in Nagoya, Japan on Saturday, October...
Clinical Trial
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
Cannabix Technologies Delivers BreathLogix Alcohol Screening Device to Oilfield Transportation Services Company
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the...
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experienceVANCOUVER, British Columbia and BOSTON, Oct....
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to...
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7%...
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025...
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International ConferenceAddition of TUS to...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial...
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously...
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct....
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs...
MOEA DoIT Showcases 65 Cutting-Edge Technologies at TIE
Unveiling AI Clothing Sorting System and New Equipment for Depression Treatment TAIPEI, Oct. 16, 2025 /PRNewswire/ -- The Department of...
C-Path’s Disease Modeling Coalition Begins Global Pediatric IBD Work from European Hub
AMSTERDAM, Oct. 16, 2025 /PRNewswire/ -- Critical Path Institute® (C-Path) today announced the official launch of the Critical Path Disease...
The Lustgarten Foundation Gathered Nation’s Foremost Pancreatic Cancer Experts for Annual Scientific Advisory Board Meeting
COLD SPRING HARBOR, N.Y., Oct. 15, 2025 /PRNewswire/ -- The Lustgarten Foundation, the world's largest private funder of pancreatic cancer...
Introducing ICON Strategic Solutions FSP Services: How This Model Supports Sponsors in Korea, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into how ICON Strategic Solutions (ISS) delivers Functional Service Provider (FSP) services that outperform...
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...